Navigation Links
Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
Date:2/22/2011

CINCINNATI, Feb. 22, 2011 /PRNewswire/ -- Prasco Laboratories announced today it has signed a distribution and supply agreement with Shire US Manufacturing, Inc. for mesalamine controlled-release capsules.  As part of the agreement, Prasco, LLC is prepared to market the authorized generic version of PENTASA® (mesalamine) Controlled-Release Capsules, at Shire's request, immediately upon any entrance into the United States market of an approved ANDA for any generic mesalamine product which is AB-rated to PENTASA®.  (At the present time, the FDA has not approved any ANDA for PENTASA®.)  The authorized generic will be marketed in the United States in 250 mg and 500 mg strengths under the Prasco label.

"We are excited to have established this new business relationship with Shire," stated Prasco Chief Executive Officer, E. Thomas Arington.  "Patients and pharmacists alike benefit when a company such as Shire commits to maintaining the supply of brand-identical medication through the Prasco Authorized Generic business model," Arington concluded.

PENTASA® is a registered trademark of Ferring A/S Corp.

About Prasco

Prasco is a privately-held pharmaceutical company located in Cincinnati, OH which specializes in Authorized Generics.  Prasco Authorized Generics provide brand pharmaceutical companies with a strategic lifecycle management solution. Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.  


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
2. Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam
3. Prasco to Market Authorized Generic of ZEGERID®
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):